226 related articles for article (PubMed ID: 29207011)
1. Astragaloside IV prevents kidney injury caused by iatrogenic hyperinsulinemia in a streptozotocin‑induced diabetic rat model.
He KQ; Li WZ; Chai XQ; Yin YY; Jiang Y; Li WP
Int J Mol Med; 2018 Feb; 41(2):1078-1088. PubMed ID: 29207011
[TBL] [Abstract][Full Text] [Related]
2. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-κB-mediated inflammatory genes expression.
Gui D; Huang J; Guo Y; Chen J; Chen Y; Xiao W; Liu X; Wang N
Cytokine; 2013 Mar; 61(3):970-7. PubMed ID: 23434274
[TBL] [Abstract][Full Text] [Related]
3. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.
Chen J; Chen Y; Luo Y; Gui D; Huang J; He D
Eur J Pharmacol; 2014 Aug; 736():86-94. PubMed ID: 24809932
[TBL] [Abstract][Full Text] [Related]
4. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.
Wang ZS; Xiong F; Xie XH; Chen D; Pan JH; Cheng L
BMC Nephrol; 2015 Mar; 16():44. PubMed ID: 25886386
[TBL] [Abstract][Full Text] [Related]
5. Astragaloside IV prevents high glucose-induced podocyte apoptosis via downregulation of TRPC6.
Yao XM; Liu YJ; Wang YM; Wang H; Zhu BB; Liang YP; Yao WG; Yu H; Wang NS; Zhang XM; Peng W
Mol Med Rep; 2016 Jun; 13(6):5149-56. PubMed ID: 27109610
[TBL] [Abstract][Full Text] [Related]
6. Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF‑κB pathway under high glucose conditions.
Sun L; Li W; Li W; Xiong L; Li G; Ma R
Int J Mol Med; 2014 Jul; 34(1):167-76. PubMed ID: 24718766
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective mechanisms of Astragaloside IV in cisplatin-induced acute kidney injury.
Yan W; Xu Y; Yuan Y; Tian L; Wang Q; Xie Y; Shao X; Zhang M; Ni Z; Mou S
Free Radic Res; 2017; 51(7-8):669-683. PubMed ID: 28750561
[TBL] [Abstract][Full Text] [Related]
8. Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR‑mediated autophagy.
Zhu Y; Su Y; Zhang J; Zhang Y; Li Y; Han Y; Dong X; Li W; Li W
Mol Med Rep; 2021 Jun; 23(6):. PubMed ID: 33846768
[TBL] [Abstract][Full Text] [Related]
9. Renal protection of in vivo administration of tempol in streptozotocin-induced diabetic rats.
Luan J; Li W; Han J; Zhang W; Gong H; Ma R
J Pharmacol Sci; 2012; 119(2):167-76. PubMed ID: 22673147
[TBL] [Abstract][Full Text] [Related]
10. Astragaloside IV attenuates apoptosis of hypertrophic cardiomyocyte through inhibiting oxidative stress and calpain-1 activation.
Mei M; Tang F; Lu M; He X; Wang H; Hou X; Hu J; Xu C; Han R
Environ Toxicol Pharmacol; 2015 Nov; 40(3):764-73. PubMed ID: 26433482
[TBL] [Abstract][Full Text] [Related]
11. Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo.
Gui D; Guo Y; Wang F; Liu W; Chen J; Chen Y; Huang J; Wang N
PLoS One; 2012; 7(6):e39824. PubMed ID: 22745830
[TBL] [Abstract][Full Text] [Related]
12. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid.
Mao ZM; Shen SM; Wan YG; Sun W; Chen HL; Huang MM; Yang JJ; Wu W; Tang HT; Tang RM
J Ethnopharmacol; 2015 Sep; 173():256-65. PubMed ID: 26226437
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation.
Zhang Y; Tao C; Xuan C; Jiang J; Cao W
Oxid Med Cell Longev; 2020; 2020():9542165. PubMed ID: 32855769
[TBL] [Abstract][Full Text] [Related]
14. Effects of Astragaloside IV on diabetic nephropathy in rats.
Lu WS; Li S; Guo WW; Chen LL; Li YS
Genet Mol Res; 2015 May; 14(2):5427-34. PubMed ID: 26125738
[TBL] [Abstract][Full Text] [Related]
15. Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway.
Lei X; Zhang BD; Ren JG; Luo FL
Life Sci; 2018 Aug; 206():77-83. PubMed ID: 29792879
[TBL] [Abstract][Full Text] [Related]
16. Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats.
Lei X; Zhang L; Li Z; Ren J
Drug Des Devel Ther; 2018; 12():2785-2793. PubMed ID: 30233141
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β1 and type IV collagen expression in rats.
Qi MY; Kai-Chen ; Liu HR; Su YH; Yu SQ
J Ethnopharmacol; 2011 Dec; 138(3):731-6. PubMed ID: 22027446
[TBL] [Abstract][Full Text] [Related]
18. Ibuprofen attenuates nephropathy in streptozotocin‑induced diabetic rats.
Liu YW; Zhu X; Cheng YQ; Lu Q; Zhang F; Guo H; Yin XX
Mol Med Rep; 2016 Jun; 13(6):5326-34. PubMed ID: 27109015
[TBL] [Abstract][Full Text] [Related]
19. A combination of the main constituents of Fufang Xueshuantong Capsules shows protective effects against streptozotocin-induced retinal lesions in rats.
Jian W; Yu S; Tang M; Duan H; Huang J
J Ethnopharmacol; 2016 Apr; 182():50-6. PubMed ID: 26692279
[TBL] [Abstract][Full Text] [Related]
20. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways.
Malik S; Suchal K; Khan SI; Bhatia J; Kishore K; Dinda AK; Arya DS
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F414-F422. PubMed ID: 28566504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
